Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Fluidigm Corp (FLDM)

6.13   0.05 (0.82%) 06-18 08:09
Open: 6.03 Pre. Close: 6.08
High: 6.2301 Low: 6.03
Volume: 744,937 Market Cap: 460M
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments, consumables, and services to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. Fluidigm Corporation sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.233 - 6.264 6.264 - 6.295
Low: 5.958 - 5.99 5.99 - 6.022
Close: 6.079 - 6.129 6.129 - 6.18

Technical analysis

as of: 2021-06-17 4:43:47 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 7.28     One year: 8.50
Support: Support1: 5.49    Support2: 5.04
Resistance: Resistance1: 6.23    Resistance2: 7.28
Pivot: 5.81
Moving Average: MA(5): 6.11     MA(20): 5.78
MA(100): 5.23     MA(250): 6.02
MACD: MACD(12,26): 0.24     Signal(9): 0.21
Stochastic oscillator: %K(14,3): 89.89     %D(3): 90.72
RSI: RSI(14): 63.14
52-week: High: 12.45  Low: 3.36  Change(%): 61.3
Average Vol(K): 3-Month: 124855  10-Days: 94906

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
FLDM has closed below upper band by 21.6%. Bollinger Bands are 12.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 17 Jun 2021
Fluidigm Corp (FLDM) gains 0.8220% for June 17 - Equities.com

Wed, 16 Jun 2021
Fluidigm Corp (FLDM) falls -0.6540% for June 16 - Equities.com

Mon, 10 May 2021
Fluidigm gains after report that activist takes 11% stake, may push for unit sale - Seeking Alpha

Thu, 08 Apr 2021
Fluidigm Announces Conference Call and Webcast of First Quarter 2021 Financial Results - Yahoo Finance

Wed, 10 Feb 2021
Fluidigm Announces Fourth Quarter and Full Year 2020 Financial Results - Yahoo Finance

Wed, 10 Feb 2021
Fluidigm (FLDM) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. (M) 75
Shares Float (M) 64
% Held by Insiders 0.97
% Held by Institutions 93.23
Shares Short (K) 8,040
Shares Short P. Month (K) 10,590

Stock Financials

EPS -0.740
EPS Est This Year -1.950
EPS Est Next Year -1.300
Book Value (p.s.) 1.870
Profit Margin -38.38
Operating Margin -36.94
Return on Assets (ttm) -10.8
Return on Equity (ttm) -36.2
Qtrly Rev. Growth 37.5
Gross Profit (p.s.) 0.625
Sales Per Share 1.843
EBITDA (p.s.) -0.627
Qtrly Earnings Growth
Operating Cash Flow (M) -15
Levered Free Cash Flow (M) -5

Stock Valuations

PE Ratio -8.28
PEG Ratio
Price to Book value 3.28
Price to Sales 3.33
Price to Cash Flow -29.80

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.